Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
NewsMoncef Slaoui, who helped lead Operation Warp Speed under the Trump administration, was removed from a medical device startup's board over allegations of sexual harassment. -
NewsPfizer and Moderna each agreed to supply 100 million doses of COVID-19 vaccine to the U.S. by the end of March. With just under three weeks left, both companies have their work cut out for them. -
President Biden has promised enough vaccines for every U.S. adult by the end of May. But first, Pfizer and Moderna have an earlier deadline: 100 million doses each by March 31.
-
Pharmaceutical giant Merck has not had success with its own COVID-19 vaccine, but has entered a deal to produce vaccines for Johnson & Johnson, who could use the help after production shortfalls.
-
NewsThe Food and Drug Administration is working on a playbook for how it could greenlight vaccine tweaks. Studies in hundreds of people, rather than tens of thousands, seem likely. -
NewsThe two companies producing COVID-19 vaccines for use in the United States will have to raise production to meet contractual goals of 100 million doses each by the end of March. -
Moderna is rapidly increasing production of COVID-19 vaccine for the U.S., and Pfizer is lagging behind. NPR looks at the production trends to see what it means for vaccination drives.
-
NewsThe two companies making COVID-19 vaccines each promised to deliver 100 million doses to the federal government by the end of March. So far, they appear to be running behind. -
The COVID-19 vaccine rollout faces another bottleneck: Pfizer and Moderna may be unable to fulfill contractual promises to deliver 100 million doses a piece to the federal government by March 31.
-
A federal manufacturing contract to increase COVID-19 vaccine production has an unusual clause that could move a company's employees and their families to the front of the vaccination line.
